全文获取类型
收费全文 | 189篇 |
免费 | 12篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 14篇 |
基础医学 | 16篇 |
口腔科学 | 2篇 |
临床医学 | 32篇 |
内科学 | 46篇 |
皮肤病学 | 2篇 |
神经病学 | 3篇 |
特种医学 | 19篇 |
外科学 | 28篇 |
综合类 | 2篇 |
预防医学 | 10篇 |
眼科学 | 4篇 |
药学 | 19篇 |
肿瘤学 | 9篇 |
出版年
2021年 | 7篇 |
2020年 | 5篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 3篇 |
2014年 | 8篇 |
2013年 | 12篇 |
2011年 | 3篇 |
2010年 | 8篇 |
2009年 | 2篇 |
2008年 | 10篇 |
2007年 | 11篇 |
2006年 | 4篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 1篇 |
2002年 | 3篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 6篇 |
1998年 | 10篇 |
1997年 | 5篇 |
1996年 | 12篇 |
1995年 | 5篇 |
1994年 | 2篇 |
1993年 | 10篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 7篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1978年 | 1篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 3篇 |
1970年 | 1篇 |
1962年 | 1篇 |
1961年 | 1篇 |
1958年 | 1篇 |
1956年 | 3篇 |
1955年 | 1篇 |
排序方式: 共有206条查询结果,搜索用时 15 毫秒
21.
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study 下载免费PDF全文
Gian Paolo Fadini MD Giancarlo Zatti MD Ileana Baldi PhD Daniele Bottigliengo Agostino Consoli Andrea Giaccari MD Giorgio Sesti Angelo Avogaro MD for the DARWIN‐TD network 《Diabetes, obesity & metabolism》2018,20(7):1781-1786
In randomized controlled trials (RCTs), sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors have been shown to confer glycaemic and extra‐glycaemic benefits. The DARWIN‐T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs those receiving selected comparators (dipeptidyl peptidase‐4 inhibitors, gliclazide, or glucagon‐like peptide‐1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281 217, the analysis included 17 285 patients initiating dapagliflozin or comparator glucose‐lowering medications (GLMs), 6751 of whom had a follow‐up examination. At baseline, participants starting dapagliflozin were younger, had a longer disease duration, higher glycated haemoglobin (HbA1c) concentration, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin changed during the study period. Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLMs were also within the expected range, based on RCTs. This real‐world study shows an initial channelling of dapagliflozin to difficult‐to‐treat patients. Nonetheless, dapagliflozin provided significant benefits with regard to glucose control, body weight and blood pressure that were in line with findings from RCTs. 相似文献
22.
23.
The between-run accuracy and reproducibility of vapor-alcohol control tests associated with quantitative evidential breath-alcohol testing in the field were evaluated. Control samples were generated at six separate sites with 34 degrees C TOXITEST II breath-alcohol simulators and analyzed by infrared spectrometry with Model 5000-D intoxilyzers in the recirculation mode. Control test results at target alcohol concentrations of 0.060, 0.080, 0.090, 0.100, 0.110, and 0.120 g/210 L (n = 779) were combined and analyzed by standard statistical methods. Results were correlated with target values, and the signed and absolute differences were calculated and analyzed. Data treatment included ANOVA, linear regression analysis, t statistics, and relative and cumulative frequency distributions of the differences. We found the performance of these current generation simulators in the field to be similarly satisfactory to that obtained in our laboratory evaluation. We further found that vapor-alcohol control samples generated with these devices conformed to established formal requirements and that they can serve as an effective quality assurance measure in evidential breath-alcohol analysis. 相似文献
24.
25.
Mark Daniels Stephanie N. DuBose David M. Maahs Roy W. Beck Larry A. Fox Rose Gubitosi-Klug Lori M. Laffel Kellee M. Miller Heather Speer William V. Tamborlane Michael J. Tansey for the TD Exchange Clinic Network 《Diabetes care》2013,36(9):2639-2645
OBJECTIVE
To examine factors associated with clinical microalbuminuria (MA) diagnosis in children and adolescents in the T1D Exchange clinic registry.RESEARCH DESIGN AND METHODS
T1D Exchange participants <20 years of age with type 1 diabetes ≥1 year and urinary albumin-to-creatinine ratio (ACR) measured within the prior 2 years were included in the analysis. MA diagnosis required all of the following: 1) a clinical diagnosis of sustained MA or macroalbuminuria, 2) confirmation of MA diagnosis by either the most recent ACR being ≥30 mg/g or current treatment with an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB), and 3) no known cause for nephropathy other than diabetes. Logistic regression was used to assess factors associated with MA.RESULTS
MA was present in 329 of 7,549 (4.4%) participants, with a higher frequency associated with longer diabetes duration, higher mean glycosylated hemoglobin (HbA1c) level, older age, female sex, higher diastolic blood pressure (BP), and lower BMI (P ≤ 0.01 for each in multivariate analysis). Older age was most strongly associated with MA among participants with HbA1c ≥9.5% (≥80 mmol/mol). MA was uncommon (<2%) among participants with HbA1c <7.5% (<58 mmol/mol). Of those with MA, only 36% were receiving ACEI/ARB treatment.CONCLUSIONS
Our results emphasize the importance of good glycemic and BP control, particularly as diabetes duration increases, in order to reduce the risk of nephropathy. Since age and diabetes duration are important nonmodifiable factors associated with MA, the importance of routine screening is underscored to ensure early diagnosis and timely treatment of MA.Elevated urinary albumin excretion is an early sign of diabetic kidney disease (DKD). The American Diabetes Association (ADA) recommends screening for microalbuminuria (MA) annually in people with type 1 diabetes after 10 years of age and 5 years of diabetes duration, with a diagnosis of MA requiring two of three tests to be abnormal (1). Early diagnosis of MA is important because effective treatments exist to limit the progression of DKD (1). However, although reduced rates of MA have been reported over the past few decades in some (2–4) but not all (5,6) studies, it has been suggested that the development of proteinuria has not been prevented but, rather, has been delayed by ∼10 years and that further improvements in care are needed (7).Limited data exist on the frequency of a clinical diagnosis of MA in the pediatric population with type 1 diabetes in the U.S. Our aim was to use the data from the T1D Exchange clinic registry to assess factors associated with MA in 7,549 children and adolescents with type 1 diabetes. 相似文献26.
27.
28.
Henry DA; Corcoran HL; Lewis TD; Barnhart GR; Szentpetery S; Lower RR 《Radiology》1989,170(2):343-350
As cardiac transplantation has become widely available, computed tomography (CT) of the chest has played a useful role in the examination of patients after heart transplantation. To determine anatomic features related to the procedure, the authors evaluated 59 scans in 46 patients who had undergone orthotopic cardiac transplantation. Aortic anastomosis (seen in 98% of scans) and altered spacing between the great vessels (83%) proved to be the most common and most reliable findings. Other features including atrial anastomosis, high main pulmonary artery segment, remnant superior vena cava, and cardiac reorientation were also seen. Accurate interpretation of adenopathy, mediastinal abscess, and pericardial effusion will be enhanced in these patients through a better understanding of the cardiovascular-pericardial complex, which is afforded by CT. 相似文献
29.
30.